Klavax Bid

Amoxicillin and potassium clavulanate, the active ingredient in Klavax Bid, is a Penicillin beta‑lactam antibiotic with beta‑lactamase inhibitor presented as an oral tablet for oral use. It treats a range of bacterial infections in adults and children, extending coverage to beta‑lactamase‑producing organisms.

GNH USA supplies Klavax Bid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards, is manufactured under strict GMP conditions, and is distributed globally with dedicated regulatory and logistics support.

Klavax Bid, a combination beta‑lactam antibiotic, is indicated for bacterial infections affecting the respiratory, ear, urinary and skin pathways.

- Acute bacterial sinusitis: reduces symptoms and accelerates resolution of infection. - Community‑acquired pneumonia: provides broad‑spectrum coverage for typical pathogens. - Acute otitis media: treats middle‑ear infections caused by susceptible bacteria. - Uncomplicated urinary tract infections: eradicates common uropathogens. - Skin and soft‑tissue infections: effective against mixed Gram‑positive and Gram‑negative organisms.

Adverse reactions may occur with any antibiotic therapy. Most are mild and self‑limiting.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: often watery, may be self‑limited. - Rash: erythematous skin eruption. - Vomiting: occasional emesis. - Abdominal pain: crampy discomfort. - Headache: transient tension‑type pain.

Serious or Rare Side Effects: - Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention. - Anaphylaxis: rapid onset of life‑threatening allergic reaction. - Stevens‑Johnson syndrome: severe mucocutaneous blistering. - Hepatic enzyme elevation: possible liver function abnormalities. - Neutropenia: reduced white‑blood cell count. - Seizures: rare neurotoxic events in susceptible patients.

Use Klavax Bid with clinical vigilance, especially in populations at higher risk of adverse outcomes. - Renal function assessment: adjust dosing in impaired clearance. - Allergy history: avoid in patients with known penicillin or beta‑lactam allergy. - Hepatic impairment: monitor liver enzymes during prolonged therapy. - Concomitant oral contraceptives: advise on potential reduced efficacy. - Drug‑induced rash: discontinue if severe cutaneous reactions develop. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Klavax Bid may alter the pharmacokinetics or pharmacodynamics of several co‑administered drugs.

Major Interactions (Avoid): - Probenecid: increases amoxicillin plasma concentrations, raising toxicity risk. - Warfarin: potentiates anticoagulant effect, requiring INR monitoring. - Methotrexate: may increase serum levels, leading to enhanced toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible reduction in contraceptive efficacy. - Allopurinol: heightened risk of skin rash. - Carbapenems: potential antagonistic effect on bacterial killing.